Nasal administration

Tiziana Life Sciences PLC (TLSA: NASDAQ) Clinical Improvements for 2nd SPMS Patient

Retrieved on: 
Thursday, June 9, 2022
Cerebellum, Hospital, Gamma ray, PET, Vital signs, COVID, Research, HIV disease progression rates, SMPS, Board of High School and Intermediate Education Uttar Pradesh, Pharmacokinetics, White matter, Annual report, Neurodegeneration, Sclerosis, Disease, Interleukin 1 beta, Type 1 diabetes, Inflammation, Blood, IND, Brain, FDA, GLOBE, Patient, Pulmonary fibrosis, Nasal administration, RESEARCH, Harvard University, Zacks, Immune system, Incidence, Compliance, KOL, NASDAQ, Cytokine, IL-6, Multiple sclerosis, NSCLC, 40, Authorization, Safety, Thalamus, Medical imaging, Pharmaceutical industry, Vaccine, SPMS, Foralumab

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences PLC (NASDAQ: TLSA) announced positive clinical results for its second secondary progressive multiple sclerosis (SMPM) patient in a June 8th press release. The ~40 year old individual that was enrolled as the second patient in the trial exhibited clinical improvements on several measures, including positron emission tomography (PET) analysis, neurologic exam and the timed 25-foot walk test after three months of treatment. The results from the second patient are consistent with the results from the first patient which were reported in a March 10 press release. Based on the data gathered from the first two subjects, Tiziana has requested and the FDA has cleared enrollment of eight more eligible SMPS patients to receive intranasal foralumab, a fully human anti-CD3 monoclonal antibody therapy, under the Expanded Access Program.

Key Points: 
  • The second patient was diagnosed with SPMS in 2014 and over the subsequent eight years, the magnitude of his disability increased.
  • See link here for the discussion on the results for the first patient and detailed background on SPMS.
  • In the clinical sphere, investigators observed improvements in the 25-foot walk test and the neurologic exam for patient #2.
  • Intranasal Foralumabs First SPMS Patient: 3- and 6-Month Data, KOL Discussion
    On January 10, 2022, Tiziana provided a progress update for its first patient in the evaluation of intranasal foralumab in SPMS.

Winmate's new 14"rugged tablet delivers an extensive experience on a big screen for the harshest environments

Retrieved on: 
Monday, June 6, 2022
Automotive industry, GIS, Mark (given name), Food, Intel Core, TB, Infrastructure, Data collection, Government, Apple Thunderbolt Display, Ecosystem, Nasal administration, MDM, Architecture, Technology, Securities Industry Automation Corporation, PCI Express, Tablet, Dust, Microsoft Windows, Water, Efficiency, Engineering, Marine Military Academy, Mobile phone, Surveying, Health care

TAIPEI, June 6, 2022 /PRNewswire/ -- Winmate, a rugged computing industry leader, announced its new M140TG 14-inch extreme rugged tablet designed to provide field users mobility and connectivity needed to help them stay productive.

Key Points: 
  • The new rugged tablet is also IP-65 rated for protection against dust, dirt, and water.
  • The M140TG Rugged extreme tablet has been drop tested from 4ft and has been built to withstand -20 to 60 Fahrenheit temperatures.
  • For those in need of extended battery life, Winmate offers an optional dual hot-swappable battery architecture and an on-the-go charging ecosystem for uninterrupted operation.
  • Winmate's M140TG extreme rugged tablet and handhelds are used in various geospatial applications, including land surveys, construction survey, and forensics mapping.

Novel Drug From Neuro-Bio Effective in a Mouse Model of Alzheimer’s Disease

Retrieved on: 
Wednesday, April 6, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Spinal cord, Brain, Neuroscience, Alzheimer's disease, Neurodegeneration, Non-executive director, Human, Regulation, Medication, Patent, Â, Acetylcholinesterase, Neuro, Research, Hippocampus, Cell damage, Pathology, Associate, University of Oxford, Neuropharmacology, Parkinson's disease, CEO, Amyloid, Center, Experimental Brain Research, Neuroprotection, T14, Nasal administration, Neurotoxicity, UCLA, Light, Medicines and Healthcare products Regulatory Agency, Disease, Neurology, Pharmaceutical industry, Fine chemical, Vaccine, Medical imaging, Medicine, NEURO-BIO, NBP14

Neuro-Bio Ltd , a biotechnology company developing a first-in-class treatment for neurodegenerative disease, finds its new drug candidate effectively treats the signs of neurodegeneration in a mouse model of Alzheimers disease.

Key Points: 
  • Neuro-Bio Ltd , a biotechnology company developing a first-in-class treatment for neurodegenerative disease, finds its new drug candidate effectively treats the signs of neurodegeneration in a mouse model of Alzheimers disease.
  • Publishing their work in Alzheimers & Dementia: Translational Research & Clinical Interventions (TRCI) , Neuro-Bio researchers, in collaboration with the drug discovery company Evotec SE, UCLA, and Kings College London studied the ability of their patented drug, NBP14, to combat neurodegeneration in an established mouse model of Alzheimers disease.
  • The results underscore the effectiveness of Neuro-Bios drug candidate and represent a remarkable step forward towards the treatment of Alzheimers disease in humans.
  • Modulatory Effects of a Novel Cyclized Peptide in Reducing the Expression of Markers Linked to Alzheimer's Disease.

Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 30, 2022
BDCA2, Risk, Polycystic kidney disease, Pizzicato, SEC, Research, Mab, EGFR, MD, ASCO, Nasdaq, AATD, GLOBE, Quarter, Autoimmune disease, Autosome, ADPKD, Haemophilia A, Successor, Secondary research, Omicron, Industry, NT1, CNTA, Neoplasm, Chief medical informatics officer, Toxicity, Haemophilia B, Patent, Hypertensive emergency, Part, Doctor of Philosophy, Program, CD3, CVR Partners, Alpha-1 antitrypsin deficiency, Pulmonary hypertension, Narcolepsy, FDA, Patient, NFL Player's Association Financial Registration Program, Administration, Company, BMP9, PAH, D, Imgatuzumab, Oral, CD47, Cash, IND, Safety, Master of Science, COVID-19, Nasal administration, Maintenance, Research and development, Acquisition, Pharmaceutical industry, Renewable energy, Medicine, Risk management, Animal, Lixivaptan, Delta, Development, Haemophilia

R&D Expenses: $41.5 million for the Company for the quarter ended December 31, 2021, $95.7 million for the Successor for 2021.

Key Points: 
  • R&D Expenses: $41.5 million for the Company for the quarter ended December 31, 2021, $95.7 million for the Successor for 2021.
  • General & Administrative Expenses: $13.0 million for the Company for the quarter ended December 31, 2021, $42.9 million for the Successor for 2021.
  • Centessa Pharmaceuticals plc (Centessa) is a clinical-stage pharmaceutical company with a Research & Development (R&D) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients.
  • We explicitly disclaim any obligation to update any forward-looking statements except to the extent required by law.

Worldwide Intranasal Therapeutics and Drug Delivery Systems Market Distribution to 2035 - Industry Trends and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 15, 2022
Health, Pharmaceutical, Molecule, Therapy, Mortality, Nasal administration, CNS, Partnership, Geography, COVID-19, Sorrento, Brain, BBB, Lists of diseases, USD, Research, Prevalence, Administration, Population, Mucus, Industry, Pharmaceutical industry, Generic drug

The "Intranasal Therapeutics and Drug Delivery Systems Market Distribution by Target Indication, Type of Molecule and Geography: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intranasal Therapeutics and Drug Delivery Systems Market Distribution by Target Indication, Type of Molecule and Geography: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • This report features an extensive study of the current market landscape and the likely future potential associated with the intranasal therapeutics and drug delivery systems market.
  • Who are the key players engaged in the development of intranasal therapeutics and drug delivery systems?
  • What are the anticipated future trends related to intranasal therapeutics and drug delivery systems?

Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning

Retrieved on: 
Friday, March 11, 2022
Southwest Research Institute, Safety, Development, EBS, Life, Twitter, Trial of the century, Private Securities Litigation Reform Act, Marketing, Research, Public health, Therapy, Pharmacokinetics, Instagram, Office of the Assistant Secretary for Preparedness and Response, U.S. Department of Commerce Office of Security, Emergent BioSolutions, BARDA, Nasal administration, Risk, Emergent, NYSE, GLOBE, Solution, Human services, Biomedical Advanced Research and Development Authority, SEC, Office of Inspector General, U.S. Department of Health and Human Services, Vaccine, Assistant, LinkedIn, Pharmaceutical industry

Emergents R&D efforts are grounded in our mission to protect and enhance life, said Kelly Warfield, Ph.D., senior vice president, research and development at Emergent BioSolutions.

Key Points: 
  • Emergents R&D efforts are grounded in our mission to protect and enhance life, said Kelly Warfield, Ph.D., senior vice president, research and development at Emergent BioSolutions.
  • We are committed to advancing unique programs like SIAN, which addresses the need for an easily administered first-line treatment for cyanide poisoning.
  • This Phase 1, open label, single ascending dose clinical study plans to enroll 70 healthy males or non-pregnant females between the ages of 18 to 45.
  • Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements.

Tiziana Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Months with Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody

Retrieved on: 
Thursday, March 10, 2022
Massachusetts General Hospital, Safety, Multiple sclerosis, Industry, SDMT, Gamma ray, Cytokine, Company, Crohn's disease, Foralumab, MS, FDA, Prion, Microglia, Neurodegeneration, PET, Autoimmunity, IV, Neurology, CNS, Serum, MD, Parkinson's disease, Nasal administration, Degenerative disease, Inflammation, AMCS, Mab, EDSS, Patient, IL-6, Program, Central nervous system, Lists of diseases, Technology, Nerve, Expanded Disability Status Scale, Harvard Medical School, COVID-19, Immunotherapy, Alzheimer's disease, HMS, BWH, SPMS, Nuclear medicine, Medical imaging, Pharmaceutical industry, Vaccine, Regulatory T cell

Consistent with clinical and PET observations, intranasally administered foralumab also downregulated serum levels of pro-inflammatory cytokines, including interferon-gamma (IFN-g), interleukin (IL-18), IL-1 and IL-6, which are associated with multiple sclerosis pathogenesis and progression.

Key Points: 
  • Consistent with clinical and PET observations, intranasally administered foralumab also downregulated serum levels of pro-inflammatory cytokines, including interferon-gamma (IFN-g), interleukin (IL-18), IL-1 and IL-6, which are associated with multiple sclerosis pathogenesis and progression.
  • Clinical evaluation showed improvement in Timed 25-Foot Walk Test (T25FW), 9-Hole Peg Test (9HPT) and Symbol Digit Modality Test (SDMT).
  • We are extremely pleased with the tolerability of intranasal foralumab and with the positive clinical and PET imaging responses observed after completion of six months of dosing in the first patient.
  • The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made.

Tiziana Enrolls Second Patient in Ongoing Intranasal Foralumab Evaluation for Secondary Progressive Multiple Sclerosis

Retrieved on: 
Monday, January 10, 2022
Safety, Natalizumab, Mab, PET, Harvard Medical School, Nasal administration, Industry, MS, Patient, Brain, Clinical, BWH, IND, SPMS, NASDAQ, BIIB, Interim, Crohn's disease, Program, EDSS, Food, Expanded Disability Status Scale, Harvard University, Immunotherapy, Database, Neurology, Company, Cytokine, Technology, Positron emission tomography, Degenerative disease, Multiple sclerosis, Frontiers Media, COVID-19, FDA, Inflammation, Autoimmunity, GLOBE, NEW, IV, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Toxic leukoencephalopathy, Massachusetts General Hospital, Pharmaceutical industry, Brigham, Regulatory T cell, Foralumab

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, is pleased to announce that the U.S. Food and Drug Administration (FDA) allowed enrollment of a second patient in the ongoing clinical treatment of secondary progressive multiple sclerosis (SPMS) with intranasally administered foralumab, a fully human anti-CD3 monoclonal antibody, at the Brigham and Women’s Hospital (BWH), Harvard University, Boston, MA.

Key Points: 
  • Treatment of the second patient is expected to begin during January 2022 with interim clinical data after 3 out of 6 months of treatment expected in April 2022.
  • The Investigators at BWH will be monitoring detailed safety, neurological, and Positron Emission Tomography (PET) to evaluate microglial activation in this patient.
  • The ongoing treatment of the first patient continues, and six months of dosing is expected to be completed by the end of March 2022.
  • To date, this patient has not shown signs of treatment intolerance or toxicities and appears to be responding well to treatment.

Satsuma Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 9, 2021
NDA, Safety, Migraine, Achievement, Therapy, Plasma, DHE, Shuping Yang commencement speech controversy, Clinical trial, SAN, European Patent Convention, Security (finance), Terminology, ASCEND, Priority right, Freedom, D, COVID-19, Treatment, Nasal administration, Pain, Company, New Drug Application, International Headache Society, U.S. Securities and Exchange Commission, Research, D&O, Triangle Park (Quezon City), GLOBE, Dihydroergotamine, Patent, Nasdaq, Patient, European Patent Office, Risk, FDA, General counsel, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported financial results for the third quarter of 2021 and provided a corporate update.

Key Points: 
  • (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported financial results for the third quarter of 2021 and provided a corporate update.
  • Ms. Harsch is a highly regarded and established pharmaceutical industry professional who brings over 20 years of legal, corporate governance, corporate transaction, and operating experience to the Satsuma Board of Directors.
  • Research and development expenses were $10.2 million for the third quarter 2021, compared to $8.8 million for the same period of 2020.
  • Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product, STS101, for the acute treatment of migraine.

AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Studies of Ampligen as a Potential Early-Onset Therapeutic for COVID-19

Retrieved on: 
Tuesday, September 28, 2021
Food, Patent, Mortality, Clinical trial, Cancer, Ichinohe, PSLRA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Antiviral drug, Immunity, AIM, Private Securities Litigation Reform Act, Utah, Degenerative disease, FDA, Institute, Drug discovery, Lists of diseases, Company, Utah State University, Disease, Trial of the century, COVID-19, Severe acute respiratory syndrome coronavirus 2, Research, Safety, NYSE, Nasal administration, GLOBE, Pharmaceutical industry, Vaccine

In addition to studying efficacy and safety, the new Phase 2 protocols include exploratory endpoints that the company believes could support its recently filed provisional patent application.

Key Points: 
  • In addition to studying efficacy and safety, the new Phase 2 protocols include exploratory endpoints that the company believes could support its recently filed provisional patent application.
  • We believe the clearly defined exploratory endpoints for the upcoming trials will substantially validate the significant potential of Ampligen.
  • With a SARS-CoV-1 virus mouse models, Ampligen demonstrated 100% protective survival benefit compared to 100% mortality in a saline control group.
  • There is the potential for delays in clinical trial enrollment and reporting because of the COVID-19 medical emergency.